Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Follicular 1Colitis, Ulcerative 1

Interventions

Rituximab 59Cyclophosphamide 29fludarabine phosphate 20Bortezomib 16Filgrastim 15Tacrolimus 12Mycophenolic Acid 12Methotrexate 12Radiotherapy 11Peripheral Blood Stem Cell Transplantation 11Cyclosporine 11Antilymphocyte Serum 11Whole-Body Irradiation 10fludarabine 8Etoposide 8venetoclax 7sargramostim 7idelalisib 7ibritumomab tiuxetan 7Melphalan 7Lenalidomide 7Cord Blood Stem Cell Transplantation 7Busulfan 7Bendamustine Hydrochloride 7Vincristine 6Prednisone 6Granulocyte Colony-Stimulating Factor 6obinutuzumab 5Gemcitabine 5umbralisib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Lymphoma, Follicular × NX-13 × Clear all
NCT05785715 2025-07-01

Study to Evaluate the Clinical Activity and Safety of Oral NX-13 in Moderate to Severe Ulcerative Colitis

AbbVie

Phase 2 Terminated
81 enrolled
Lymphoid

Colitis, Ulcerative, Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡